Core Viewpoint - Bayer is preparing a plan to reach a settlement regarding the large-scale lawsuits related to the carcinogenicity of its herbicide "Roundup" in Missouri, and if the settlement fails, the company may consider filing for bankruptcy for its subsidiary Monsanto [1] Group 1 - Bayer has already paid approximately $10 billion to resolve disputes concerning the carcinogenic claims associated with "Roundup" [1]

拜耳股价在法兰克福市场下跌7%。 ...

Core Insights - Bayer AG reported a net profit of 1.3 billion euros (approximately $1.45 billion) for Q1 2025, a decrease from 2 billion euros in the same period last year [1] - The company confirmed its outlook for the full year 2025 at constant currencies despite current tariff announcements and mitigation measures [1] - Bayer is reorganizing its Crop Science division in Germany to enhance competitiveness globally [1][2] Financial Performance - Adjusted earnings were 65 cents, surpassing the consensus estimate of 38 cents [5] - Sales reached $14.45 billion (13.74 billion euros), exceeding the consensus of $13.39 billion [5] - EBITDA before restructuring and litigation charges fell 7% year-on-year to 4 billion euros in Q1 [5] - Sales in the agricultural business decreased by 3.3% to 7.58 billion euros [5] - Sales of prescription medicines increased by 4.1% to 4.548 billion euros [5] - Significant growth rates were recorded for new products, including a 77.5% increase for the cancer drug Nubeqa (515 million euros) and an 86.6% increase for Kerendia (161 million euros) [5] Strategic Changes - Bayer will focus on advanced, strategic products that provide clear benefits to farmers and are difficult for generic manufacturers to replicate [2] - The company plans to cease operations in Frankfurt by late 2028 as part of its restructuring efforts [2][3] - The Dormagen site will remain Bayer's main production hub for crop protection products, but it will be streamlined to maintain competitiveness [3] - Bayer will stop producing generic active ingredients and formulations that are widely available at lower prices globally [3] - The changes are expected to affect approximately 200 of the 1,200 employees at the Dormagen site, primarily in active ingredient production and formulation [3]

拜耳首席执行官：（关于关税问题）我们目前没有立即计划重新审视我们全球平衡的制造布局。 ...

拜耳股价上涨6.1%，该公司第一季度业绩超出预期。 ...

拜耳第一季度 净利润为12.99亿欧元。 ...

拜耳第一季度调整后息税折旧及摊销前利润40.9亿欧元，预估38.8亿欧元。 第一季度销售额137.4亿欧元，预估135.2亿欧元。 第一季度经调整EBITDA利润率29.7％，预估28.5％。 第一季度负自由现金流15.3亿欧元，预估负25.3亿欧元。 第一季度核心每股收益2.49欧元，预估2.34欧元。 第一季度期末负债净额342.6亿欧元，预估347.9亿欧元。 ...

智通财经5月13日电，拜耳第一季度净利润为12.99亿欧元。 ...

市场消息：拜耳计划出售在法兰克福的生产业务。 ...

Bayer (BAYRY) announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK inhibitor.The drug is now fully approved in the United States for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation that has spread or for those who are not eligible for surgery. The drug was approved for patients who did not have any satisfactory alternative treatment or ...